^
over1year
Trial suspension • CAR T-Cell Therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification
|
Torisel (temsirolimus) • BPX-603
over2years
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=220, Recruiting, Bellicum Pharmaceuticals | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Dec 2023 --> Dec 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification
|
Torisel (temsirolimus) • BPX-603
almost4years
Clinical • New P1/2 trial • CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification
|
Torisel (temsirolimus) • BPX-603